IgLON Family Member 5 (IgLON5) Antibody, IgG by CBA-IFA With Reflex to Titer, CSF
Also known as: IGLON5 CSF
Use
Aids in the diagnosis of neurodegenerative disease and limbic encephalitis. May be used to monitor treatment response in individuals who are antibody positive. The presence of IgLON5 antibodies may be associated with sleep disorders, bulbar symptoms, gait problems, cognitive dysfunction, movement disorders, or dysautonomia. IgLON5 autoimmune neurologic/neurodegenerative disorders may be paraneoplastic, but tumor type is variable.
Special Instructions
If IgLON5 antibody IgG is positive, then IgLON5 antibody IgG titer will be added. Additional charges apply.
Limitations
A negative test result does not rule out a diagnosis of an autoimmune neurologic disorder. Interpretation of any antineural antibody test requires clinical correlation. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 96481-7
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.15 mL
Container
ARUP standard transport tube
Collection Instructions
Separate CSF.
Causes for Rejection
Grossly hemolyzed or contaminated specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month (Three freeze/thaw cycles are acceptable) |